Another Rituximab Debuts In India But No Price Contest?

The privately owned Indian firm Hetero has launched rituximab, its biosimilar version of Roche's MabThera/Rituxan, in India, trailing a clutch of local peers onto the market, although it is not yet clear what price advantages it may have over rivals.